FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2078175238> ?p ?o ?g. }

• W2078175238 endingPage "1764" @default.
• W2078175238 startingPage "1762" @default.
• W2078175238 abstract "Sirs, We present two patients with central nervous system (CNS) disease associated with Sjogren’s syndrome (SjS) and positive for antiaquaporin-4 water channel autoantibodies (AQP4-Ab) who were treated successfully with tacrolimus. Tacrolimus is an immunosuppressant that acts as a calcineurin inhibitor and suppresses T helper 2 (Th2) cells [1]. Tacrolimus may also act as a neuroprotectant by reducing axonal and myelin damage, as shown in a mouse model of experimental autoimmune encephalomyelitis [2]. SjS is a chronic autoimmune disease characterized by lymphocytic infiltration of the exocrine glands. SjS-associated inflammation sometimes spreads into the CNS (CNS–SjS), occasionally mimics relapsing-remitting multiple sclerosis (MS), and inflammation often involves the brain, spinal cord, and optic nerve [3]. Neuromyelitis optica (NMO) is also a relapsing inflammatory disease of the CNS, characterized by severe attacks of optic nerve neuritis and longitudinally extensive transverse myelitis [4]. NMO is distinguished from MS by the presence of AQP4-Ab and differences in the distribution of inflammatory lesions and pathological findings. Combination therapy with a corticosteroid and azathioprine is the current standard treatment for preventing NMO relapse [5]; however, some patients are refractory to this therapy. Approximately 3% of patients with NMO have coexisting systemic lupus erythematosus (SLE) or SjS, and CNS–SjS patients with optic nerve neuritis or longitudinal myelitis (conditions called ‘‘NMO spectrum disorder’’) often present with positive findings for AQP4-Ab [4, 6, 7]. To our knowledge, this is the first reported assessment of tacrolimus in patients with CNS–SjS with AQP4-Ab. This treatment was approved by the ethical committee of our university, and the patients provided written informed consent. A 48-year-old female (Patient 1, Fig. 1) was admitted to the hospital with rapidly progressive nausea, hiccups, dysphagia, and drowsiness. Magnetic resonance imaging (MRI) revealed T2 hyperintensities of the hypothalamus bilaterally and the dorsal medulla oblongata. After three courses of intravenous high-dose methylprednisolone (IHMP, 1 g/day for 3 days in one course), the patient recovered completely, except for mild dysphagia. One year after the first attack, she developed limb weakness. Laboratory test results revealed high levels of anti-Ro (SSA) antibodies and positive antinuclear antibody. The Schirmer test and the Saxon test revealed decreased salivary secretion (Table 1). She was diagnosed with CNS–SjS [8]. She experienced nine attacks during the entire disease course, and we started treatment with oral tacrolimus during her ninth admission. No recurrent attacks have been observed for 49 months since the start of this treatment. T. Fukuda (&) H. Shiraishi H. Nakamura A. Tsujino Y. Nishiura M. Motomura K. Eguchi First Department of Internal Medicine, Graduate School of Biomedical Sciences, Nagasaki University, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan e-mail: taku-ngs@umin.ac.jp" @default.
• W2078175238 created "2016-06-24" @default.
• W2078175238 creator A5003002099 @default.
• W2078175238 creator A5016544055 @default.
• W2078175238 creator A5017765343 @default.
• W2078175238 creator A5044442302 @default.
• W2078175238 creator A5048008812 @default.
• W2078175238 creator A5050020581 @default.
• W2078175238 creator A5055072474 @default.
• W2078175238 creator A5078973714 @default.
• W2078175238 creator A5081071954 @default.
• W2078175238 creator A5084299259 @default.
• W2078175238 date "2009-05-26" @default.
• W2078175238 modified "2023-09-26" @default.
• W2078175238 title "Efficacy of tacrolimus in Sjögren’s syndrome-associated CNS disease with aquaporin-4 autoantibodies" @default.
• W2078175238 cites W1998541832 @default.
• W2078175238 cites W2009308901 @default.
• W2078175238 cites W2054658992 @default.
• W2078175238 cites W2083149517 @default.
• W2078175238 cites W2092149677 @default.
• W2078175238 cites W2107941546 @default.
• W2078175238 cites W2133934007 @default.
• W2078175238 cites W2167385753 @default.
• W2078175238 cites W2167714980 @default.
• W2078175238 doi "https://doi.org/10.1007/s00415-009-5175-6" @default.
• W2078175238 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19468783" @default.
• W2078175238 hasPublicationYear "2009" @default.
• W2078175238 type Work @default.
• W2078175238 sameAs 2078175238 @default.
• W2078175238 citedByCount "3" @default.
• W2078175238 countsByYear W20781752382017 @default.
• W2078175238 countsByYear W20781752382020 @default.
• W2078175238 crossrefType "journal-article" @default.
• W2078175238 hasAuthorship W2078175238A5003002099 @default.
• W2078175238 hasAuthorship W2078175238A5016544055 @default.
• W2078175238 hasAuthorship W2078175238A5017765343 @default.
• W2078175238 hasAuthorship W2078175238A5044442302 @default.
• W2078175238 hasAuthorship W2078175238A5048008812 @default.
• W2078175238 hasAuthorship W2078175238A5050020581 @default.
• W2078175238 hasAuthorship W2078175238A5055072474 @default.
• W2078175238 hasAuthorship W2078175238A5078973714 @default.
• W2078175238 hasAuthorship W2078175238A5081071954 @default.
• W2078175238 hasAuthorship W2078175238A5084299259 @default.
• W2078175238 hasBestOaLocation W20781752382 @default.
• W2078175238 hasConcept C118552586 @default.
• W2078175238 hasConcept C126322002 @default.
• W2078175238 hasConcept C142724271 @default.
• W2078175238 hasConcept C15755913 @default.
• W2078175238 hasConcept C159654299 @default.
• W2078175238 hasConcept C163764329 @default.
• W2078175238 hasConcept C16568411 @default.
• W2078175238 hasConcept C203014093 @default.
• W2078175238 hasConcept C2779134260 @default.
• W2078175238 hasConcept C2779889316 @default.
• W2078175238 hasConcept C2909675724 @default.
• W2078175238 hasConcept C2911091166 @default.
• W2078175238 hasConcept C71924100 @default.
• W2078175238 hasConceptScore W2078175238C118552586 @default.
• W2078175238 hasConceptScore W2078175238C126322002 @default.
• W2078175238 hasConceptScore W2078175238C142724271 @default.
• W2078175238 hasConceptScore W2078175238C15755913 @default.
• W2078175238 hasConceptScore W2078175238C159654299 @default.
• W2078175238 hasConceptScore W2078175238C163764329 @default.
• W2078175238 hasConceptScore W2078175238C16568411 @default.
• W2078175238 hasConceptScore W2078175238C203014093 @default.
• W2078175238 hasConceptScore W2078175238C2779134260 @default.
• W2078175238 hasConceptScore W2078175238C2779889316 @default.
• W2078175238 hasConceptScore W2078175238C2909675724 @default.
• W2078175238 hasConceptScore W2078175238C2911091166 @default.
• W2078175238 hasConceptScore W2078175238C71924100 @default.
• W2078175238 hasIssue "10" @default.
• W2078175238 hasLocation W20781752381 @default.
• W2078175238 hasLocation W20781752382 @default.
• W2078175238 hasLocation W20781752383 @default.
• W2078175238 hasOpenAccess W2078175238 @default.
• W2078175238 hasPrimaryLocation W20781752381 @default.
• W2078175238 hasRelatedWork W1985651348 @default.
• W2078175238 hasRelatedWork W2001182481 @default.
• W2078175238 hasRelatedWork W2004206192 @default.
• W2078175238 hasRelatedWork W2008466367 @default.
• W2078175238 hasRelatedWork W2027404516 @default.
• W2078175238 hasRelatedWork W2060355472 @default.
• W2078175238 hasRelatedWork W2120185406 @default.
• W2078175238 hasRelatedWork W2325085845 @default.
• W2078175238 hasRelatedWork W4249826870 @default.
• W2078175238 hasRelatedWork W4322720186 @default.
• W2078175238 hasVolume "256" @default.
• W2078175238 isParatext "false" @default.
• W2078175238 isRetracted "false" @default.
• W2078175238 magId "2078175238" @default.
• W2078175238 workType "article" @default.